ReviewBlood transfusion = Trasfusione del sangue2019
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus.
Review in Blood transfusion = Trasfusione del sangue, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Guideline
- Polycythemia Vera, Thrombophilia, CTEPH, Cerebral Venous Sinus Thrombosis and Vertebral Artery Occlusion: A Case-Illustrated Narrative Review of Competing Thrombotic and Hemorrhagic Risks.Life (Basel, Switzerland) · 2026Article
- Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Anticoagulant therapy in patients with cancer and thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Review
- Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations.Cancers · 2025Article
- Risk of venous thromboembolism after discontinuing prophylactic or therapeutic anticoagulation in patients with haematologic malignancies because of thrombocytopenia.Journal of thrombosis and thrombolysis · 2025Article
- An unusual cause of fatal pulmonary embolism: A case report.Respiratory medicine case reports · 2025Article
- Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records.Frontiers in pharmacology · 2025Article
- Article
- Baseline platelet count and long-term clinical outcomes in patients with acute venous thromboembolism: a prospective cohort study.Annals of hematology · 2024Article
- Pulmonary Embolism in Critically Ill Patients-Prevention, Diagnosis, and Management.Diagnostics (Basel, Switzerland) · 2024Review
- Global hemostasis assays in acute myeloid leukemia: results of an observational prospective study.Blood transfusion = Trasfusione del sangue · 2024Observational
- The Incidence and Characteristics of Thrombosis in Patients with Immune thrombocytopenia: A Retrospective Cohort Study.International journal of general medicine · 2024Article
- Influence of thrombocytopenia on bleeding and vascular events in atrial fibrillation.Blood advances · 2023Article
- Superior sagittal sinus thrombosis in the course of mixed phenotype acute leukaemia treated with acute lymphoblastic leukaemia-like therapy-a case report.Thrombosis journal · 2023Article
- Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions.Clinical pharmacokinetics · 2023Review
- The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.Cancers · 2023Review
- Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients.Annals of hematology · 2023Observational
- Anticoagulation With Platelet Transfusions for Acute Limb Ischemia With Severe Thrombocytopenia.Cureus · 2023Article
- Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.Vascular health and risk management · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of venous thromboembolism (VTE) in patients with haematologic malignancies and thrombocytopenia is clinically challenging due to the related risks. No prospective studies or clinical trials have been carried out and, therefore, no solid evidence on this compelling issue is available.
methodsGiven this, an expert panel endorsed by the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on Thrombosis and Haemostasis was set up to produce a formal consensus, according to the RAND method, in order to issue clinical recommendations about the platelet (PLT) cut-off for safe administration of low molecular weight heparin (LMWH) in thrombocytopenic (PLT <100×10
resultsIn acute VTE, the panel suggests safe anticoagulation with LMWH at therapeutic doses for PLT between ≥50<100×10 DISCUSSION: We suggest using dose-adjusted LMWH according to PLT to optimise anticoagulant treatment in patients at high bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.